Passage Bio Announces Interim Data From First Eight Patients with GM1 Gangliosidosis In Imagine-1 Study, Safety Data Up To 28 Months Showed Dose 1 & 2 Of PBGM01 Were Well Tolerated, With Favorable Safety & Immunological Profile
Portfolio Pulse from Benzinga Newsdesk
Passage Bio has announced interim data from the first eight patients with GM1 Gangliosidosis in the Imagine-1 study. The safety data up to 28 months showed that dose 1 & 2 of PBGM01 were well tolerated, with a favorable safety & immunological profile.
August 07, 2023 | 11:36 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Passage Bio's interim data from the Imagine-1 study shows that PBGM01 was well tolerated, indicating a positive development for the company.
The positive interim data from the Imagine-1 study indicates that PBGM01, a product of Passage Bio, was well tolerated. This is a positive development for the company as it suggests the product is safe and effective, which could lead to regulatory approval and potential sales growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100